AP23573 Ridaforolimus of aurora kinases for tailored risk-adapted treatment of multiple myeloma.

e T, Meissner T, et al. Inhibition AP23573 Ridaforolimus of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood. 2009, 113:4331�?0. 113. Fiskus W, Wang Y, Joshi R, et al. Cotreatment with vorinostat enhances activity of MK-0457 against acute and chronic myelogenous leukemia cells. Clin Cancer Res. 2008, 14 : 6106�?5. 114. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004, 10 :262�?. 115. Dai Y, Chen S, Venditti CA, et al. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood. 2008, 112:793�?04. 116. Okabe S, Tauchi T, Ohyashiki K.
Efficacy of MK-0457 and in combination with vorinostat against Philadelphia TKI258 PDGFR inhibitor chromosome positive acute lymphoblastic leukemia cells. Ann Hematol. 2010, 89:1081�?. 117. Samuel TA, Fiskus W, Wang Y, et al. Novel aurora kinases-targeted combination therapy for breast cancers. J Clin Oncol. 2008, 26 abstr 14569. 118. Hoover RR, Harding MW. Synergistic activity of the aurora kinase inhibitor MK-0457 with idarubicin, Ara-C, and inhibitors of BCR-Abl. Blood. 2006, 108 abstr 1384. 119. Hoover RR, Harding MW. Activity of the aurora kinase inhibitor MK-0457 in combination with taxotere. J Clin Oncol. 2007, 25 abstr 14069. 120. Hoover RR, Furey B, Pollard J, Harding M. Synergistic activity of the aurora kinase inhibitor MK-0457 with erlotinib. Proc Am Assoc Cancer Res. 2008, 49 abstr 4016. 121. Tibes R, Giles F, McQueen T, et al.
Translational in vivo and in vitro studies in patients with acute myeloid leukemia, chronic myeloid leukemia and myeloproliferative disease treated with MK-0457, a novel aurora kinase, FLT3, JAK2, and BCR-Abl inhibitor. Blood. 2006, 108 abstr 1362. 122. Giles F, Cortes J, Bergstrom DA, et al. MK-0457, a novel multikinase inhibitor, is active in patients with chronic myeloid leukemia and acute lymphocytic leukemia with the T315I BCRAbl resistance mutation and patients with refractory JAK2-positive myeloproliferative diseases. Blood. 2006, 108 abstr 253. 123�? Papayannidis C, Iacobucci I, Soverini S, et al. Innovative phase I study of concomitant and consecutive treatment with dasatinib and MK-0457 in refractory Ph+ CML and ALL patients. J Clin Oncol. 2009, 27 abstr 7080.
Trial demonstrating effect of predominant BCR-Abl inhibitor and multitargeted kinase inhibitor when used in sequence. 124. Fancelli D, Moll J, Varasi M, et al. 1,4,5,6-tetrahydropyrrolo pyrazoles: identification of a potent aurora kinase inhibitor with favorable antitumor kinase inhibition profile. J Med Chem. 2006, 49:7247�?1. 125. Carpinelli P, Ceruti R, Giorgini ML, et al. PHA-739358, a potent inhibitor of aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther. 2007, 6 :3158�?8. Green et al. Page 20 Expert Opin Drug Discov. Author manuscript, available in PMC 2012 March 1. NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript 126. Benten D, Keller G, Quaas A, et al. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Neoplasia. 2009, 11 :934�?4. 127. Gontarewicz A, Balabanov S, Keller G, et al. Simultaneous targeting of aurora kinases and BCRAbl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-Abl mutations including T315I. Blood. 2008, 111:4355�?4. 128. Steeghs N, Eskens F, Gelderblom H, et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol. 2009, 27:5094�?01. 129. Cohen RB, Jones SF, Aggarwal C

Related posts:

  1. Ridaforolimus MK-8669 in its pseudokinase Cathedral sharing plans.
  2. The threonine kinases that handle cell cycle progression as therapeutic targets.
  3. Mubritinib EGFR inhibitor O the r Multiple opportunities HDAC enzymes in the treatment of various M
  4. IkB Signaling of Aurora B kinase with AZD1152 ask results in radiosensitization
  5. Lacosamide the IGFR pathway is a rational strategy in adrenocortical

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

© Apoptosis|apoptosis inhibitor|apoptosis pathway